HealthCare Global Enterprises (HCG) investor relations material

Executive summary

• Achieved revenue of INR 6,951 million in Q1 FY27, up 13% year-on-year, with broad-based growth across centers and strong patient demand.

• Adjusted EBITDA rose 20% year-on-year to INR 1,339 million, with margin improvement to 19.4% from 18.2% in Q1 FY26.

• Profit after tax surged 190% year-on-year to INR 138 million, with PAT margin at 2.0%.

• Completed strategic exit from the fertility business in June 2026, sharpening focus on core oncology.

• North Bangalore hospital commenced operations, adding over 120 beds and advanced MR-LINAC technology.

Financial highlights

• Reported EBITDA for the quarter was INR 1,223 million; adjusted EBITDA (excluding North Bangalore losses and one-offs) rose 20% year-on-year to INR 1,339 million.

• EBITDA margin improved to 19.4% from 18.2% in Q1 FY26.

• Non-institutional business revenue grew 17% year-on-year, with its contribution rising from 67% to 69%.

• Operating cash flow before working capital changes was INR 125 crore; net cash flow from operations was INR 70 crore.

• In-patient volume (excluding fertility) rose 11% year-on-year to 84,147; ARPP (excluding fertility) grew 2% year-on-year to INR 85,943.

Outlook and guidance

• Confident in delivering mid-teen revenue growth from existing and new centers, with a focus on margin improvement.

• Long-term EBITDA margin target is 24%-25% in four to five years; 21%-22% expected in the next two years.

• North Bangalore hospital expected to reach optimal utilization (60%-65%) in 3-4 years and monthly breakeven within the year.

• Targeting addition of 1,000 beds by FY30, with 60% through brownfield expansion and significant capex planned.

• Strategic priorities include optimizing the existing network, improving efficiency, investing in growth, and enhancing patient experience.